Literature DB >> 28455964

Bispecific protein targets prostate cancer.

Antony W Burgess1.   

Abstract

Entities:  

Keywords:  PSMA; dsRNA; immunotherapy; polyIC; prostate cancer

Year:  2017        PMID： 28455964      PMCID： PMC5482589          DOI： 10.18632/oncotarget.17372

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


× No keyword cloud information.
  7 in total

1.  Trends in Metastatic Breast and Prostate Cancer.

Authors:  H Gilbert Welch; David H Gorski; Peter C Albertsen
Journal:  N Engl J Med       Date:  2016-02-11       Impact factor: 91.245

Review 2.  Leverage nonclinical development of bispecifics by translational science.

Authors:  Andreas Baumann; Stephanie Fischmann; Guenter Blaich; Matthias Friedrich
Journal:  Drug Discov Today Technol       Date:  2016-10-27

3.  From the Guest Editor: The Spectrum of Treatment of Metastatic Prostate Cancer: Present and Future.

Authors:  Daniel P Petrylak
Journal:  Cancer J       Date:  2016 Sep/Oct       Impact factor: 3.360

4.  Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Philip W Kantoff; James L Gulley; Cesar Pico-Navarro
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

5.  EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice.

Authors:  Alexei Shir; Manfred Ogris; Wolfgang Roedl; Ernst Wagner; Alexander Levitzki
Journal:  Clin Cancer Res       Date:  2010-12-30       Impact factor: 12.531

Review 6.  Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.

Authors:  Shankar Vallabhajosula; Anastasia Nikolopoulou; Yuliya S Jhanwar; Gurveen Kaur; Scott T Tagawa; David M Nanus; Neil H Bander; Stanley J Goldsmith
Journal:  Curr Radiopharm       Date:  2016

7.  PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses.

Authors:  Yael Langut; Nufar Edinger; Efrat Flashner-Abramson; Naomi Melamed-Book; Mario Lebendiker; Yael Levi-Kalisman; Shoshana Klein; Alexander Levitzki
Journal:  Oncotarget       Date:  2017-04-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.